Glycogen Synthase Kinase 3

A glycogen synthase kinase that was originally described as a key enzyme involved in glycogen metabolism. It regulates a diverse array of functions such as CELL DIVISION, microtubule function and APOPTOSIS.

Also Known As:

Networked: 493 relevant articles (20 outcomes, 55 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Avila, Jesús: 19 articles (01/2014 - 05/2003)
2.	Hernández, Félix: 15 articles (09/2015 - 08/2003)
3.	Lucas, José J: 13 articles (09/2015 - 01/2004)
4.	Woodgett, James R: 11 articles (09/2015 - 04/2003)
5.	Eldar-Finkelman, Hagit: 10 articles (09/2013 - 03/2002)
6.	Medina, Miguel: 9 articles (02/2014 - 09/2007)
7.	Martinez, Ana: 8 articles (03/2014 - 07/2002)
8.	Wang, Jian-Zhi: 7 articles (01/2013 - 05/2005)
9.	Koh, Seong-Ho: 7 articles (10/2012 - 10/2003)
10.	Patel, Satish: 7 articles (03/2011 - 09/2004)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 09/01/2010 - "Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease." 01/01/2005 - "The study demonstrated that overactivation of GSK-3 induced hyperphosphorylation of neurofilament and suggested that in vitro overactivation of GSK-3 resulted in neurofilament hyperphosphorylation and this may be the underlying mechanism for Alzheimer's disease." 01/01/2016 - "Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease." 05/01/2015 - "When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compound showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396. " 01/01/2014 - "Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). "
2.	Schizophrenia (Dementia Praecox) 06/01/2004 - "This may indicate that investigation of the genetics of GSK-3 beta regulation holds promise for understanding some of the biochemical underpinnings of schizophrenia." 04/01/2008 - "Previous studies have suggested that GSK-3 beta might act as a potential candidate locus for schizophrenia susceptibility. " 01/01/2005 - "Taken together, these studies suggest that low GSK-3 in postmortem brain of schizophrenic patients is a late consequence of perinatal neurodevelopmental insult in schizophrenia. " 06/01/2003 - "The present study aimed to evaluate the possible involvement of neuroleptic treatment in the decrease of GSK-3 in schizophrenia. " 09/01/2014 - "A link with schizophrenia is suggested by the antipsychotic drug-induced GSK-3 regulation and by the involvement of the Akt/GSK-3 pathway in dopaminergic neurotransmission. "
3.	Ischemia 08/19/2011 - "Beta isoform-specific inhibition of GSK-3 by dominant negative GSK-3β in transgenic mice (Tg-DnGSK-3β) or in heterozygous GSK-3β knock-out mice (GSK-3β+/-) significantly increased, whereas activation of GSK-3β in constitutively active GSK-3β knock-in mice (βKI) significantly decreased, myocardial ischemic injury after prolonged ischemia. " 08/01/2008 - "Moreover, direct pharmacological inhibition of GSK-3 catalytic activity with structurally diverse inhibitors before or after ischemia failed to recapitulate conditioning protection. " 07/01/2008 - "However, expression of GSK-3 beta in transient intrauterine ischemia group increased (P < 0.05). " 01/01/2008 - "sFRP-1 overexpression in endothelium specifically reversed the inactivation of GSK-3 beta and increased neovascularization in ischemia-induced angiogenesis in mouse hindlimb. " 07/11/2008 - "These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. "
4.	Neoplasms (Cancer) 12/11/2015 - "Tumor Suppressor Lzap Suppresses Wnt/β-Catenin Signaling to Promote Zebrafish Embryonic Ventral Cell Fates via the Suppression of Inhibitory Phosphorylation of Glycogen Synthase Kinase 3." 12/01/2015 - "Glycogen synthase kinase 3 in Wnt signaling pathway and cancer." 09/01/2015 - "Multiple inhibitors to EGFR, PI3K, mTOR, GSK-3, Raf, MEK and hedgehog (HH) have been developed and are being evaluated in various cancers. " 08/27/2015 - "GSK-3 inhibitors may be useful in targeting mTORC1 and lysosomal acidification for cancer therapy. " 08/27/2015 - "Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth."
5.	Insulin Resistance 10/01/2013 - "GSK-3 inhibition did not affect weight but improved insulin resistance, also on cellular level. " 08/01/1999 - "Taken together, our studies suggest an unsuspected link between increased GSK-3 activity and development of insulin resistance and type 2 diabetes in fat tissue of C57BL/6J mice, and implicate GSK-3 as a potential factor contributing to susceptibility of C57BL/6J mice to diet-induced diabetes." 09/01/2010 - "The evidence to date supports an important role of GSK-3 dysfunction in the multifactorial etiology of insulin resistance in skeletal muscle. " 06/01/2008 - "The high-fat-fed lean Zucker rat: a spontaneous isocaloric model of fat-induced insulin resistance associated with muscle GSK-3 overactivity." 09/01/2007 - "Recognizing GSK-3 and Hsps in the pathogenesis of insulin resistance, the central common feature of the metabolic syndrome, and type 2 diabetes will expand our understanding of the disease, offering new therapeutic options."

Related Drugs and Biologics

1.	Lithium
2.	Insulin (Novolin)
3.	Glucose (Dextrose)
4.	Phosphotransferases (Kinase)
5.	Glycogen Synthase (Synthase I)
6.	Proteins (Proteins, Gene)
7.	tau Proteins (tau Protein)
8.	Cyclosporine (Ciclosporin)
9.	Valproic Acid (Valproate, Semisodium)
10.	indirubin

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Heterologous Transplantation (Xenotransplantation)
4.	Intraperitoneal Injections
5.	Drug Therapy (Chemotherapy)